MEI Pharma (Biopharma, Biotechnology) — Funding, Investors & Signals 2026

MEI Pharma

Committed to the development of novel, best-in-class, cancer therapies intended to provide improved outcomes to patients

Founded 2000

San Diego, United States 121 employees Post Ipo Equity Total: $160.36M Biopharma, Biotechnology

MEI Pharma, a San Diego-based clinical-stage pharmaceutical company, is dedicated to developing and commercializing novel, best-in-class cancer therapies with the aim of improving patient outcomes. The company's approach involves understanding and leveraging the mechanisms and properties of its drug candidates to optimize the balance between efficacy and tolerability, meeting the specific needs of cancer patients. Each pipeline candidate possesses a unique mechanism of action targeting pathways involved in various hematological malignancies and solid tumors. One of MEI Pharma's key pipeline candidates is Zandelisib (formerly known as ME-401), which is undergoing multiple clinical trials to evaluate its effectiveness in patients with B-cell malignancies, with the intention to support marketing approvals from the FDA and other regulatory authorities globally. Additionally, Voruciclib, a potent inhibitor of CDK9, is being explored in combination with standard therapies for the treatment of hematologic malignances and solid tumors. Another promising drug candidate is ME-344, a mitochondrial inhibitor being evaluated for the treatment of solid tumors. Founded in 2000, MEI Pharma focuses on Biopharma and Biotechnology industries. The company secured a significant investment of $51.75M in Post-IPO Equity at 19 December 2019. MEI Pharma upholds its dedication to its mission and workplace values, including dedication, shared commitment, personal accountability, mutual trust, and fiscal discipline. For individuals interested in joining a team of friendly, dedicated, experienced, and collaborative professionals, more details can be found at meipharma.com/careers.

Funding Stage	Amount	Investors	Lead Investors	Date
Post-IPO Equity	••••••	-		19 Dec 2019
Post-IPO Equity	••••••	7	•••• ••••	15 May 2018
Post-IPO Equity	••••••	1		01 Jul 2016
Post-IPO Equity	••••••	2		05 Nov 2012
Post-IPO Equity	••••••	-		31 May 2011

Funding Stage

Amount

Investors

Lead Investors

Date

Post-IPO Equity

••••••

19 Dec 2019

Post-IPO Equity

••••••

•••• ••••

15 May 2018

Post-IPO Equity

••••••

01 Jul 2016

Post-IPO Equity

••••••

05 Nov 2012

Post-IPO Equity

••••••

31 May 2011

FAQ About MEI Pharma

Committed to the development of novel, best-in-class, cancer therapies intended to provide improved outcomes to patients

MEI Pharma was founded in 2000.

MEI Pharma is headquartered in San Diego, United States.

MEI Pharma operates in the following industries: Biopharma, Biotechnology.

MEI Pharma has approximately 121 employees.

MEI Pharma has completed 5 funding rounds, raising a total of $160.36M. The latest funding stage is Post Ipo Equity.

Top alternatives and competitors to MEI Pharma include Tarveda Therapeutics, Avistone Biotechnology Co., Inc, Endeavor BioMedicines, XNK Therapeutics, ProfoundBio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

MEI Pharma and Tarveda Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

MEI Pharma

General Information

Track MEI Pharma

Discover More

About MEI Pharma

Funding Rounds & Investors (5)

MEI Pharma Alternatives & Competitors

FAQ About MEI Pharma

Don't just browse. Track.